Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM)

Brief description of study

The study is designed to rapidly evaluate new therapies to treat the overactive immune response that has been observed in some COVID-19 patients. The study will look at three different study drugs called infliximab (Remicade), abatacept (Orencia), and cenicriviroc (CVC). All three drugs are not approved by the FDA to treat COVID-19 and are considered investigational. This study will compare the effects and safety of remdesivir when used with and without each of the three study drugs.


Clinical Study Identifier: s20-01701
ClinicalTrials.gov Identifier: NCT04593940
Principal Investigator: Sam Parnia.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.